Hantz Financial Services Inc. Decreases Stock Holdings in ResMed Inc. (NYSE:RMD)

Hantz Financial Services Inc. cut its holdings in ResMed Inc. (NYSE:RMD) by 2.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 44,134 shares of the medical equipment provider’s stock after selling 1,134 shares during the quarter. Hantz Financial Services Inc.’s holdings in ResMed were worth $10,093,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of RMD. Peak Financial Advisors LLC purchased a new position in shares of ResMed in the 4th quarter worth approximately $2,972,000. Principal Financial Group Inc. lifted its position in ResMed by 2.9% in the third quarter. Principal Financial Group Inc. now owns 186,776 shares of the medical equipment provider’s stock worth $45,596,000 after buying an additional 5,284 shares during the last quarter. Retireful LLC purchased a new position in ResMed during the third quarter worth $742,000. Asset Management One Co. Ltd. increased its position in ResMed by 5.1% during the third quarter. Asset Management One Co. Ltd. now owns 58,860 shares of the medical equipment provider’s stock valued at $14,369,000 after acquiring an additional 2,878 shares during the last quarter. Finally, Empowered Funds LLC raised its stake in shares of ResMed by 284.3% in the third quarter. Empowered Funds LLC now owns 8,208 shares of the medical equipment provider’s stock valued at $2,004,000 after acquiring an additional 6,072 shares during the period. Institutional investors own 54.98% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on RMD. Robert W. Baird lifted their price target on shares of ResMed from $280.00 to $283.00 and gave the stock an “outperform” rating in a research note on Friday, October 25th. Piper Sandler assumed coverage on ResMed in a research report on Friday, January 10th. They set a “neutral” rating and a $252.00 target price for the company. StockNews.com raised ResMed from a “hold” rating to a “buy” rating in a research note on Tuesday, October 15th. KeyCorp raised their price target on ResMed from $251.00 to $266.00 and gave the stock an “overweight” rating in a research note on Friday, October 25th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of ResMed in a research report on Friday, October 25th. One research analyst has rated the stock with a sell rating, six have given a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, ResMed presently has an average rating of “Moderate Buy” and a consensus price target of $238.40.

ResMed Price Performance

RMD opened at $249.25 on Wednesday. The company has a market capitalization of $36.59 billion, a price-to-earnings ratio of 33.27, a PEG ratio of 1.78 and a beta of 0.70. The company has a current ratio of 2.92, a quick ratio of 1.91 and a debt-to-equity ratio of 0.13. ResMed Inc. has a 12-month low of $170.56 and a 12-month high of $260.49. The business’s fifty day simple moving average is $239.80 and its 200-day simple moving average is $235.71.

Insider Buying and Selling

In related news, insider Justin Leong sold 6,160 shares of the business’s stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $243.09, for a total value of $1,497,434.40. Following the completion of the transaction, the insider now owns 21,718 shares of the company’s stock, valued at $5,279,428.62. The trade was a 22.10 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Witte Jan De sold 796 shares of the stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $248.81, for a total value of $198,052.76. Following the sale, the director now directly owns 6,723 shares in the company, valued at $1,672,749.63. This trade represents a 10.59 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 11,099 shares of company stock valued at $2,719,385 over the last three months. 0.71% of the stock is owned by company insiders.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.